UNSPSC 51373404: Acetaminophen/codeine/guaifenesin/phenylpropanolamine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF) which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.

The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate.

UNSPSC 51373404 Acetaminophen/codeine/guaifenesin/phenylpropanolamine is a Commodity code that does not align with recent state and local procurement activity posted under this code. The two opportunities identified are Seminole County, Florida's procurement of naloxone and drug deactivation systems (IFB, due Jul 26, 2023) and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products (due Mar 26, 2026). Neither solicitation specifically targets the acetaminophen/codeine/guaifenesin/phenylpropanolamine combination named by the code. The MMCAP RFP seeks manufacturers of generic pharmaceuticals and OTC products across multiple therapeutic categories for distribution through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC), with national applicability across participating state and local government facilities including Oregon. The naloxone procurement appears completely unrelated to the code's scope, representing instead a harm-reduction initiative focused on opioid reversal agents and drug deactivation systems.

Recent activity under this code appears limited to a single tangentially relevant cooperative purchasing opportunity. The MMCAP RFP, posted January 20, 2026 with proposals due March 26, 2026, represents the primary signaling mechanism for state and local government demand for generic pharmaceuticals in this category, with awards effective July 1, 2026 and performance spanning the upper Midwest and Pacific Northwest. Evaluation will weight price competitiveness at 75 percent, with fixed pricing, cGMP and Drug Supply Chain Security Act compliance, EDI capability, and the ability to transact through authorized wholesalers as significant factors. Vendors must carry commercial general liability coverage of $5,000,000 per occurrence and meet FDA requirements with expiration dates at least one year from manufacture. The code exhibits minimal recent targeted procurement activity specific to the acetaminophen/codeine/guaifenesin/phenylpropanolamine combination, signaling either low demand, misclassification in the taxonomy, or consolidation of such products within broader generic-pharmaceutical cooperative purchasing contracts.